Enfusion is set to announce its earnings results on Tuesday, March 7th, with analysts expecting earnings of $0.03 per share for the quarter. Enfusion’s (NYE:ENFN) shares opened at $10.87 on Tuesday, with a 12-month low of $7.80 and a high of $17.13. The firm’s market cap is $1.24 billion, and it has a P/E ratio of -4.59 and a beta of 0.47. The company’s insiders own 40.10% of its stock.
Hedge funds and institutional investors have taken notice of Enfusion, with recent modifications to their holdings of the business. Lazard Asset Management LLC purchased a new stake in Enfusion in the 4th quarter valued at $28,000, while State of Wyoming now owns 9,139 shares of the company’s stock worth $88,000.
Wall Street analysts have recently issued reports on Enfusion, with Bank of America downgrading the shares from “neutral” to “underperform” and lowering its price objective for the company to $10.00. Meanwhile, Morgan Stanley upgraded the stock from “equal weight” to “overweight” and lowered its target price for the stock from $13.00 to $12.00.
Enfusion Inc Stock Forecast
Enfusion Inc’s stock is projected to reach an average target price of $12.10 over the next twelve months based on the forecasts of four analysts, who have given the stock a “Hold” rating on average. Stock Target Advisor’s analysis of Enfusion Inc is “Slightly Bearish,” supported by seven negative signals and four positive signals. As of the last closing, the stock price was $10.87, down 2.25% in the past week, 7.57% in the past month, and 33.88% in the past year.
Company Overview:
Enfusion, Inc. is a software-as-a-service provider for the investment management industry with operations in various regions including the US, Europe, the Middle East, Africa, and Asia Pacific. The company offers portfolio management, order and execution management, accounting/general ledger, Enfusion analytics, and technology-powered and managed services to help users analyze portfolios and automate customized visualized reports for stakeholders. Enfusion was founded in 2021 and is headquartered in Chicago.
